William Morice II, M.D., Ph.D., highlights data-driven reasons health systems benefit from the lab service line and strategies to bolster performance.

Review the art of delivering clear, constructive feedback; tips for navigating potentially challenging conversations with respect; highlighting the importance of positive feedback.

As drug trends and diagnostic technologies evolve, toxicology must adapt to meet the demands of healthcare, workplace safety, and public health—focusing on opioid detection, CBD use, patient-centered testing, and new methods like saliva analysis, each bringing distinct challenges and opportunities. The following podcast episodes feature chemistry-related interviews that discuss these topics.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and CEO and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D. In this episode, they discuss Dr. Morice’s new role as CEO and president of Mayo Clinic Laboratories (MCL), his patient-centered vision for the future, and how MCL is leading positive changes in the diagnostics industry.

Topic highlights include: Mayo Clinic health system experts say mental health issues on the rise, New York declares a state of emergency over polio, U.S. reaches medical milestone with millionth organ transplant

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Ann Moyer, M.D., Ph.D., associate professor of laboratory medicine and pathology, assistant professor[...]

Joseph Maleszewski, M.D., and Marie-Christine Aubry, M.D., explain how Mayo Clinic Laboratory can provide definitive diagnosis of primary ciliary dyskinesia (PCD). Mayo Clinic's expertise and technology have earned the laboratory's designation as the sole center of excellence for diagnosing this rare respiratory disorder.

In Mayo Clinic’s Advanced Diagnostics Laboratory, there are dozens of projects underway at once to develop new technologies, discover novel findings, validate new tests, and support physicians in providing advanced patient care. For example, researchers are using phage immunoprecipitation sequencing (PhIP-Seq) to discover new serological biomarkers for autoimmune diseases. In a recent study using PhIP-Seq, Mayo Clinic researchers discovered a previously unknown antibody marker for immune-mediated rippling muscle disease (iRMD). This finding will support testing options and accurate diagnosis of iRMD, helping physicians treat patients with iRMD and restore their quality of life.

Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for alcohol use.

This week's research roundup features: A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction

Topic highlights include: Five ways you’ll exercise smarter in the future, Scientists discovered an antibody that can take out all COVID-19 variants, Mayo launches accelerator dedicated to gene and cell therapies

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and CEO and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice discuss current challenges in lab medicine and what it means to be a laboratory leader, including innovation, test stewardship, and the use of digital pathology.

Darci Block, Ph.D., co-director of the Central Clinical Lab in Mayo Clinic’s Department of Laboratory Medicine and Pathology in Rochester, Minnesota, discusses how and when autoverification is used and not used to help verify the approximately 8,000 specimens that are sent to the department’s Central Clinical Lab every day.

Two leaders have been announced to lead Mayo Clinic Laboratories and other diagnostic services in the biopharma and cardiovascular spaces. William Morice II, M.D., Ph.D., has been named CEO and president and Mary Jo Williamson has been named chief administrative officer.

This week's research roundup features: Outcomes of tricuspid valve repair with artificial neochordae in pediatric and adult patients